APC and Stroke: Indeed, the anticoagulant actions of APC appear to be detrimental in this model.[14,15] However, the potential increased likelihood of bleeding complications associated with co-administration of both a fibrinolytic and anticoagulant agent means there is necessary caution over the use of APC in stroke patients.[16] Thus, APC variants with reduced anticoagulant, but normal cytoprotective function may represent attractive adjunctive therapy options.